Blog

Empire Metals Limited (LSE:EEE) has strengthened its project development capabilities through key appointments and strategic partnerships, pushing forward the Pitfield Titanium Project in Western Australia. The company has initiated bulk metallurgical testing—an essential phase in moving towards commercial production—and teamed up with Strategic Metallurgy to provide expert technical support. These efforts are focused on validating the project’s economic viability and exploring optimal mine design and product strategies, marking a pivotal step toward bringing the Pitfield mine into operation.

About Empire Metals

Empire Metals Limited is an AIM-listed and OTCQB-traded exploration and development firm concentrating on the Pitfield titanium project in Western Australia. The company’s high-grade titanium discovery at Pitfield boasts considerable scale and promising drill results, highlighting its potential as a significant resource development.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Synectics plc (LSE:SNX) has secured two major gaming contracts totaling around US$3 million, expanding its footprint in both Asian and North American markets. The deals include a US$2.5 million upgrade to the surveillance system at a prominent casino resort in Manila and a US$600,000 implementation of the Synergy software platform at a tribal gaming facility in Oklahoma. These contracts support Synectics’ growth strategy and contribute to revenue stability for the current fiscal year.

The company’s outlook is bolstered by strong financial results, positive corporate developments, and moderately favorable technical indicators. Although valuation appears fair and recent earnings data is limited, Synectics’ strategic momentum and contract wins underscore its potential for continued growth.

About Synectics

Synectics plc specializes in cutting-edge security and surveillance technology, delivering integrated solutions that enhance safety, streamline operations, and enable informed decision-making. Renowned for its technical expertise and robust partnerships, Synectics provides innovative systems that create lasting value for clients.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

McBride plc (LSE:MCB) reported a solid financial performance for the year ending June 2025, with adjusted operating profits expected to align with market forecasts. Group revenue edged up by 0.7%, while contract manufacturing volumes surged 48.9%, driven by new long-term agreements. Although private label market share remained steady, McBride made significant progress reducing net debt by £26.3 million and announced plans to reinstate annual dividends, reflecting confidence in its financial health.

The company’s shares present potential upside, supported by a strong financial rebound and favorable valuation metrics. Technical analysis offers mixed signals but does not suggest overbought conditions, indicating room for growth. Additionally, the alignment of management incentives through restricted share units (RSUs) strengthens investor confidence in McBride’s strategic direction.

About McBride

McBride plc is a leading European manufacturer specializing in private label and contract manufacturing of household and professional cleaning and hygiene products.

Craneware plc (LSE:CRW) delivered a strong financial performance for the fiscal year 2025, exceeding market expectations across key metrics. Revenue rose by 9%, supported by steady sales growth and recurring income from its Trisus Platform, while adjusted EBITDA increased by 12%. Strategic collaboration with Microsoft and ongoing AI innovation are expected to boost the company’s footprint in the US healthcare sector. Healthy cash balances and lower debt levels further strengthen Craneware’s growth prospects.

Positive financial results combined with favorable technical indicators contribute to a strong stock profile, although a relatively high price-to-earnings ratio indicates some overvaluation concerns. The recent corporate developments offer modest but positive support to investor sentiment.

About Craneware

The Craneware Group specializes in healthcare financial and operational transformation, delivering cloud-based solutions via its Trisus ecosystem to improve the efficiency of healthcare organizations. As a trusted Microsoft partner, Craneware helps clients navigate complex healthcare finance challenges, establishing itself as a key player in the industry.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Physiomics plc (LSE:PYC) has secured a new agreement with Numab Therapeutics to provide pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation services for a First-In-Human clinical study within Numab’s inflammation pipeline. This partnership marks an important expansion for Physiomics, extending its Model-Informed Drug Development expertise beyond oncology into inflammatory diseases. The project is set to start shortly and is expected to complete within six months, reinforcing Physiomics’ commitment to supporting early-stage drug development decisions.

Despite this strategic collaboration, Physiomics continues to face financial headwinds, including falling revenues and ongoing losses. Technical analysis signals a bearish market outlook. While the new contract highlights growth potential, significant valuation challenges and financial instability remain key concerns for investors.

About Physiomics plc

Physiomics specializes in advanced mathematical modelling, biostatistics, and data science to accelerate the development of novel therapeutics and personalized medicine. With a track record of supporting over 100 commercial projects, the company partners with leading biopharma firms—including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and Cancer Research UK—to optimize drug development strategies through sophisticated simulation and analysis.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

KEFI Gold and Copper PLC (LSE:KEFI) has begun the community resettlement phase for its Tulu Kapi Gold Project in Ethiopia ahead of schedule, marking a key milestone as the company moves closer to full-scale operations. Funded through KEFI’s recent capital raise, this progress supports the target to commence gold production by 2027. The initiative enjoys strong backing from the Ethiopian government alongside major international gold investors.

About KEFI Minerals

KEFI Gold and Copper PLC specializes in the exploration and development of gold and copper assets within the Arabian-Nubian Shield region, with active projects located in both Ethiopia and Saudi Arabia.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Journeo plc (LSE:JNEO) has secured a £1.2 million contract via its Danish arm, Journeo AS, to supply Intelligent Transport Systems to Umove, Denmark’s largest private public transport operator. This project, tied to Umove’s 12-year partnership with Trafikselskabet Midttrafik, will see around 100 buses outfitted with cutting-edge technology such as passenger counting and AI-driven systems. The contract strengthens Journeo’s foothold in the Nordic transport market and supports its recurring revenue streams.

The company’s outlook is buoyed by solid financial results and strategic developments, signaling robust growth and expanding market reach. While technical analysis points to a bullish momentum, investors should remain cautious amid signs of potential overbought conditions. Valuation metrics remain attractive, underpinning Journeo’s investment potential.

About Journeo plc

Journeo is a leading provider of Intelligent Transport Systems, delivering advanced solutions for public transport networks, urban areas, airports, and rail. Operating through five subsidiaries, the company partners with local governments, Network Rail, and major transport operators in Denmark and Sweden, specializing in fleet management, passenger systems, rail technology, and technical services.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Creightons plc (LSE:CRL) has released its audited results for the fiscal year ending 31 March 2025, reporting a 1.6% rise in revenue to £54.1 million, largely driven by private label sales. Profitability saw a notable rebound, with EBITDA climbing 57.9% and the company returning to a £2.5 million post-tax profit—thanks to streamlined operations, cost controls, and efficiency gains in both manufacturing and distribution.

The company also confirmed its strategic transition from the Main Market to the AIM, aimed at reducing regulatory overheads and providing greater flexibility for growth initiatives. Governance practices are evolving accordingly, with new board appointments and the adoption of the QCA Corporate Governance Code to align with AIM standards.

Although revenue growth remains modest and technical indicators suggest the stock may be entering overbought territory, recent operational improvements and structural changes present a more optimistic longer-term outlook. Valuation concerns persist, but strong cash flow and strategic repositioning are likely to support future performance.

About Creightons plc

Creightons is a UK-based manufacturer and brand owner in the beauty and wellness sector. The company specializes in private label and contract manufacturing, alongside its own branded product lines, serving a broad range of retail and consumer clients.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cordel Group PLC (LSE:CRDL) has reported an 8% year-over-year revenue increase for the fiscal year ending June 2025, reaching £4.79 million. Improved operating margins and stronger cash flow were driven by a strategic shift toward high-margin software revenues and tighter cost control. Although some revenue from recent contracts has been delayed, Cordel secured five new clients, including two major U.S. rail operators, reinforcing its global footprint.

Looking ahead, the company is ramping up investment in marketing and delivery infrastructure to support the launch of its Positive Train Control (PTC) platform, which has attracted growing international attention.

While Cordel’s top-line growth and expanding market presence are encouraging, ongoing challenges with profitability and liquidity may concern long-term investors. Still, the company’s strategic moves and contract wins suggest a promising path forward.

About Cordel Group PLC

Cordel Group is a transport technology firm delivering advanced hardware and AI-powered software solutions for infrastructure monitoring. Specializing in corridor analytics, the company helps rail and transport operators make data-driven decisions through large-scale data capture and intelligent reporting tools.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Supply@ME Capital plc (LSE:SYME) has reported a delay in receiving a US$1.2 million tranche from its US$5.15 million on-demand convertible funding agreement with Nuburu Inc. The postponement stems from financial statement restatements by Nuburu, temporarily impacting SYME’s cash flow and near-term operational flexibility. Nuburu has indicated that it expects to release the pending funds shortly, and SYME has committed to keeping stakeholders informed once the payment is completed.

About Supply@ME Capital plc

Supply@ME is a fintech company offering a unique inventory monetisation platform. It enables manufacturers and trading firms to unlock working capital by converting inventory into liquidity, without taking on traditional debt. Through partnerships with third-party inventory funders, SYME provides alternative finance solutions designed to optimize balance sheets and support business growth.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.